{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:36:48Z","timestamp":1740109008111,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2018YFA0902802"],"award-info":[{"award-number":["2018YFA0902802"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04838-0","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T12:02:22Z","timestamp":1709208142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant combination therapy (immunotherapy and chemotherapy) and treatment-related biomarkers in upper tract urothelial carcinoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Yuxuan","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-1500","authenticated-orcid":false,"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"4838_CR1","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1016\/j.xcrm.2022.100785","volume":"41","author":"G Calleris","year":"2023","unstructured":"Calleris G, Roupr\u00eat M, Seisen T et al (2023) Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756). World J Urol 41:3413\u20133420. https:\/\/doi.org\/10.1007\/s00345-023-04596-5","journal-title":"World J Urol"},{"key":"4838_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100785","volume":"3","author":"J Hu","year":"2022","unstructured":"Hu J, Chen J, Ou Z et al (2022) Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study. Cell Rep Med 3:100785. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100785","journal-title":"Cell Rep Med"},{"key":"4838_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.eururo.2020.05.039","volume":"78","author":"MR Hassler","year":"2020","unstructured":"Hassler MR, Bray F, Catto JWF et al (2020) Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature. Eur Urol 78:209\u2013220. https:\/\/doi.org\/10.1016\/j.eururo.2020.05.039","journal-title":"Eur Urol"},{"key":"4838_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmg.2007.048991","volume":"44","author":"HF Vasen","year":"2007","unstructured":"Vasen HF, M\u00f6slein G, Alonso A et al (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44:353\u2013362. https:\/\/doi.org\/10.1136\/jmg.2007.048991","journal-title":"J Med Genet"},{"key":"4838_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13059-020-02230-w","volume":"22","author":"X Su","year":"2021","unstructured":"Su X, Lu X, Bazai SK et al (2021) Comprehensive integrative profiling of upper tract urothelial carcinomas. Genome Biol 22:7. https:\/\/doi.org\/10.1186\/s13059-020-02230-w","journal-title":"Genome Biol"},{"key":"4838_CR6","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson BD, Vlachostergios PJ, Bhinder B et al (2019) Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun 10:2977. https:\/\/doi.org\/10.1038\/s41467-019-10873-y","journal-title":"Nat Commun"},{"key":"4838_CR7","doi-asserted-by":"publisher","first-page":"e006643","DOI":"10.1136\/jitc-2022-006643","volume":"11","author":"Y Song","year":"2023","unstructured":"Song Y, Peng Y, Qin C et al (2023) Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment. J Immunother Cancer 11:e006643. https:\/\/doi.org\/10.1136\/jitc-2022-006643","journal-title":"J Immunother Cancer"},{"key":"4838_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.euo.2020.04.005","volume":"4","author":"A Necchi","year":"2021","unstructured":"Necchi A, Raggi D, Giannatempo P et al (2021) Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study. Eur Urol Oncol 4:1001\u20131005. https:\/\/doi.org\/10.1016\/j.euo.2020.04.005","journal-title":"Eur Urol Oncol"},{"key":"4838_CR9","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","volume":"27","author":"T Powles","year":"2021","unstructured":"Powles T, Sridhar SS, Loriot Y et al (2021) Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med 27:2200\u20132211. https:\/\/doi.org\/10.1038\/s41591-021-01579-0","journal-title":"Nat Med"},{"key":"4838_CR10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","volume":"78","author":"MY Teo","year":"2020","unstructured":"Teo MY, Mota JM, Whiting KA et al (2020) Fibroblast growth factor receptor-3 alterationstatus is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma. Eur Urol 78:907\u2013915. https:\/\/doi.org\/10.1016\/j.eururo.2020.07.018","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04838-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04838-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04838-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:21:31Z","timestamp":1735852891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04838-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4838"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04838-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors consent for the publication of the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"110"}}